CNS Pharmaceuticals, Inc (CNSP)

Etorro trading 970x250
CNS Pharmaceuticals, Inc (CNSP) Logo

About CNS Pharmaceuticals, Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas. Address: 2100 West Loop South, Houston, TX, United States, 77027

CNS Pharmaceuticals, Inc News and around…

Latest news about CNS Pharmaceuticals, Inc (CNSP) common stock and company :

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor Innovations in Oncology Event
23 Sep, 2022 FinancialContent
Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs
23 Sep, 2022 FinancialContent
CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)
23 Sep, 2022 Yahoo! Finance

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) Event on Wednesday, September 28, 2022 at 1:00 PM ET.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment
19 Sep, 2022 FinancialContent
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM
16 Sep, 2022 FinancialContent
Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
15 Sep, 2022 FinancialContent
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
13 Sep, 2022 FinancialContent
12 Health Care Stocks Moving In Monday's After-Market Session
12 Sep, 2022 FinancialContent

Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of ...

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
09 Sep, 2022 FinancialContent
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 Sep, 2022 FinancialContent
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
07 Sep, 2022 FinancialContent
Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
07 Sep, 2022 FinancialContent
CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 Sep, 2022 Yahoo! Finance

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
01 Sep, 2022 FinancialContent
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
30 Aug, 2022 FinancialContent
Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
29 Aug, 2022 FinancialContent
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
23 Aug, 2022 FinancialContent
Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
19 Aug, 2022 FinancialContent
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
15 Aug, 2022 FinancialContent
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 Aug, 2022 Yahoo! Finance

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.

Researchers Want to Manage Cancer By Keeping Malignant Cells Restricted in Place
12 Aug, 2022 FinancialContent
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success
12 Aug, 2022 FinancialContent
Study Finds That Ketogenic Diet May Help Patients with Brain Cancer
04 Aug, 2022 FinancialContent
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market
04 Aug, 2022 FinancialContent
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
02 Aug, 2022 FinancialContent
Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring
27 Jul, 2022 FinancialContent
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting
25 Jul, 2022 FinancialContent
CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022
25 Jul, 2022 Yahoo! Finance

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today urged shareholders to vote in favor of the proposals outlined in the Company's Definitive Proxy Statement (the "Proxy") for the upcoming Annual Shareholder Meeting to be held Wednesday, July 27, 2022.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
20 Jul, 2022 FinancialContent
Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors
18 Jul, 2022 FinancialContent

CNS Pharmaceuticals, Inc (CNSP) is a NASDAQ Common Stock listed in , ,

970x250